Showing 11 posts of 11 posts found.

FDA approves Roche’s Actemra/RoActemra treatment for rare lung disease

March 5, 2021
Medical Communications Actemra, RoActemra, Roche, SEC, systemic sclerosis

Roche’s Actemra/RoActemra therapy, intended for slowing the rate of decline in pulmonary function for adults with systemic sclerosis-associated interstitial lung …


Roche’s Actemra fails to improve clinical status in COVID-19-associated pneumonia

July 29, 2020
Research and Development Actemra, COVID-19, Roche, pharma

Roche has announced the disappointing news that its therapy Actemra/RoActemra (tocilizumab) failed to improve clinical status to a statistically significant …

Roche’s rheumatoid arthritis drug Actemra shows no benefit in COVID-19 pneumonia

June 18, 2020
Research and Development Actemra, COVID-19, Roche, coronavirus

Hope is waning around the efficacy of Roche’s Actemra (tocilizumab) following the release of results from an Italian study focusing …

China approves Roche’s Actemra to fight severe complications stemming from coronavirus

March 5, 2020
Sales and Marketing Actemra, China, Roche, coronavirus, pharma

China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in …

Sanofi & Regeneron’s arthritis drug scores first approval following FDA rejection

February 1, 2017
Research and Development, Sales and Marketing Actemra, Humira, Kevzara, Regeneron, Roche, Sanofi, sarilumab

Kevzara (sarilumab), a interleukin-6 (IL06) receptor antibody developed by Sanofi and Regeneron and the first real competitor to Roche’s Actemra …


Roche’s Actemra granted Priority Review by FDA

January 24, 2017
Manufacturing and Production, Sales and Marketing Actemra, FDA, Roche, priority review

Roche’s drug, Actemra (also known as RoActemra in Europe), has been granted priority review designation by the FDA for the …

Roche granted breakthrough therapy designation by FDA

October 5, 2016
Research and Development Actemra, FDA, Giant Cell arteritis, Roche, breakthrough therapy

Roche has announced that the FDA has granted its Actembra drug breakthrough therapy designation for giant cell arteritis. The breakthrough …


Ablynx’s RA therapy matches Roche’s Actemra in Phase IIb trial

July 7, 2016
Medical Communications, Research and Development Ablynx, Actemra, Roche

Ablynx (EBR: ABLX) has presented positive data on their rheumatoid arthritis treatment candidate, ALX-0061 (vobarilizumab), in patients with rheumatoid arthritis …

Roche image

Roche buoyed by cancer drug sales

April 22, 2015
Sales and Marketing Actemra, Cancer, Esbriet, Esbriet., MabThera, Q1, Rituxan, RoActemra, Roche, Xolair, avastin, oncology

Pharma’s biggest cancer drugs maker Roche has reported strong sales growth on the back of its oncology portfolio for its …

Roche image

Oncology drives Roche profits

January 30, 2014
Sales and Marketing Actemra, Perjeta, Roche, Swiss, q4

Sales at Roche’s pharma division rose 7% year-on-year in 2013, driven largely by strong performances from its oncology portfolio. Group …

FDA approves Roche’s Actemra

January 11, 2010
Sales and Marketing Actemra, RoActemra, Roche, US, rheumatoid arthritis

Roche’s Actemra has been approved in the US for the treatment of moderately to severely active rheumatoid arthritis (RA) and …

Latest content